BlinkLab

September 2024 Quarterly Activities Report and Appendix 4C

Advancing global neurodiagnostics with strategic partnerships and regulatory milestones on a pathway to commercialisation

BlinkLab Limited (ASX:BB1) (“BlinkLab” or the “Company”) an innovative digital healthcare company leveraging smartphones, computer vision, Al and machine learning to diagnose neurodevelopmental conditions, is pleased to release its Appendix 4C and Quarterly Activity Report for the period ended 30 September 2024. During the quarter the Company made significant progress towards the launch of its upcoming FDA registration study, which is on-track to commence before the calendar year end.


Highlights

  • FDA registration study on track to commence this calendar year.
  • Strategic partnerships signed with leading outpatient mental healthcare providers in Europe, for Autism and ADM/
  • Several clinical studies in Autism, ADI-D), Frontotemporal Dementia, Functional Neurological Disorders, Spinocerebellar Ataxia, with top European and US institutions are ongoing and results are expected next calendar year.
  • Commenced regulatory work towards obtaining ISO/CE mark certifications in Europe to support future commercial launch.
  • As at 30 September 2024, the Company had a cash balance of A$5.4 million following the $7 million IPO in April.
BlinkLab was also pleased to announce several new strategic partnerships which confirmed the continuing adoption of BlinkLab's products with world-renowned research institutions. The rapid progress in making the Company's cutting-edge technology available to healthcare practitioners, families and caregivers is exciting for the BlinkLab team.

Strong progress towards initiation of FDA clinical study later this year for "BlinkLab Dx 1" We are pleased to report that, after a competitive selection process, BlinkLab are in the final stages of appointing a world-recognised Clinical Research Organisation ("CRO"), with a track record of obtaining regulatory approvals for digital healthcare and medical devices, to co­ordinate our upcoming FDA registration trial.

Throughout the quarter, the Company continued work on finalising the study protocol, engaging with FDA as well as reaching out and interacting with future US based clinical sites that will be conducting the registrational studies. Before the end of CY 2024, we expect to announce the outcomes of this work. We are excited about the progress that our regulatory and development team is making to start the FDA study that we believe will be the largest smartphone based clinical study in the world, in the field of autism diagnostics.

Strategic Partnerships with large European Mental Healthcare Providers

During the past quarter, we announced two major clinical and future commercialisation partnerships with large European mental healthcare providers. Together with Mental Care Group and INTER-PSY, BlinkLab has launched companion clinical studies in ADHD and autism, evaluating whether the Company's technology can enhance diagnostic accuracy and efficiency in clinical settings, with a future commitment to commercialise our products with these partners in Europe upon successful outcomes. With a national network of over 200 clinical centres serving over 100,000 patients annually, these partnerships are a huge endorsement of the BlinkLab smartphone-based tests and the potential to grow successfully outside the US.

Ongoing Work Towards Obtaining European Certifications of BlinkLab Product

As the Company continues to support the activities for the launch of FDA registrational study, the BlinkLab team has also initiated work towards obtaining applicable regulatory clearances to be able to launch the product outside the US.

Under the EU Medical Device Regulation (MDR) 2017/745, the BlinkLab diagnostic platform is classified as a class Ila medical device and will require CE marking of conformity before the device can be launched on the market. The conformity work will include implementation of quality management systems (IS013485 certification), usability engineering, labelling, adherence to general data protection regulation (GDPR), developing appropriate post-market surveillance plan and other activities. This work commenced during the prior quarter, and the Company will be providing ongoing updates as it moves forward towards EU certification and future launch in markets outside the US.

Ongoing Clinical Studies in Other Indications with World Leading Research Organisations

Since listing on the Australian Securities Exchange in April this year, BlinkLab has announced multiple clinical research collaborations with several world-renowned research institutions to conduct studies in mental and developmental conditions outside of autism and ADHD.

The data collected from these studies is fundamental to the Company's diagnostic platform and machine learning models, as distinguishing autism and ADHD from other psychiatric disorders in the real world is difficult due to their multidimensional phenotypes and significant overlap of symptoms and characteristics.

At BlinkLab we are trying to fundamentally change the diagnostic approach by collecting digital phenotype data from the broadest possible range of neurodevelopmental and neurodegenerative conditions. By training the model on large data sets from various diseases, we significantly improve future predictive performance of the BlinkLab application in real-world scenarios.


Click here for the full ASX Release

This article includes content from Blinklab Limited, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.

BB1:AU
The Conversation (0)
Robotic arm assembling chips with NVIDIA logo and "Tech 5" text overlay.

Tech 5: NVIDIA Results Rattle Investors, Trump Signals More Tech Deals to Come

Artificial intelligence (AI) stocks saw continued pressure this week as concerns about overvaluation weighed on the sector ahead of NVIDIA's (NASDAQ:NVDA) results release for its second fiscal quarter.

The company beat Wall Street projections on revenue, earnings and profits, but shares still fell in extended trading on Tuesday (August 26) after it reported no H20 sales to China, where competition from domestic firms is heating up.

John Murillo, chief business officer at B2BROKER, suggested the pullback could present a short-term buying opportunity for high-quality names with strong fundamentals, but cautioned that it could be the start of a broader correction.

Keep reading...Show less
NVIDIA logo.

NVIDIA Delivers Record Quarter as AI Demand Booms, but China Uncertainty Persists

NVIDIA (NASDAQ:NVDA) delivered another blockbuster quarter, reporting record revenue of US$46.7 billion for its second fiscal period as demand for artificial intelligence (AI) infrastructure continues to surge.

The chipmaking giant said sales rose 56 percent from a year earlier and 6 percent from the prior quarter, marking the ninth straight period of year-on-year revenue growth above 50 percent.

Meanwhile, NVIDIA's net income jumped 59 percent to US$26.42 billion from US$16.6 billion. Its adjusted earnings per share were US$1.05, beating analyst forecasts of US$1.01.

Keep reading...Show less
Digital globe with glowing blue patterns and network connections.

ResetData Creates New Public Sovereign AI Supercomputer in Australia

Australian cloud provider ResetData, part of Centuria Capital Group (ASX:CNI), has unveiled AI-F1, a public sovereign artificial intelligence (AI) supercomputer located in Australia.

AI-F1 offers onshore, high-performance AI computing resources for the government, academic and business sectors.

The multi-megawatt supercomputer allows customers to leverage NVIDIA's (NASDAQ:NVDA) NIM microservices, which are designed to work on machine learning and large language models.

Keep reading...Show less
Futuristic 3D microchip with glowing circuits on a blue background.

NVIDIA's Latest AI Chip Comes at Crucial Moment Before Earnings Report

Reports are circulating that NVIDIA (NASDAQ:NVDA) is quietly preparing a new artificial intelligence (AI) chip for China that would surpass the performance of its current H20 model.

The move comes as the US weighs how much access Chinese companies should have to American technology.

Two people briefed on the matter told Reuters that the chip, tentatively called the B30A, is based on NVIDIA's latest Blackwell architecture and is expected to deliver roughly half the computing power of the company’s flagship dual-die B300 accelerator card. Like the H20, the new chip is rumored to include high-bandwidth memory and NVLink interconnect technology, but would offer more power for Chinese clients.

Keep reading...Show less
Two businesspeople shaking hands over financial graphs and "Tech 5" text.

Tech 5: US Government Strikes Big Tech Deal, Perplexity Plots Expansion

Tech stocks led Wall Street to a second consecutive week of gains as a series of data releases reignited optimism about a September interest rate cut from the US Federal Reserve.

A strong consumer price index report was the catalyst, renewing anticipation that the Fed will lower rates when it meets next month. While Thursday's (August 14) less optimistic producer price index report caused a momentary pause, the tech sector's resilience — or defiance — mitigated losses and kept momentum alive.

Here's a look at the key moments that shaped the tech sector this week.

Keep reading...Show less

Latest Press Releases

Related News

×